Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster and antibody persistence study of GSK 10-valent pneumococcal conjugate vaccine in toddlers previously primed in study 10PN-PD-DIT-048
2012-000819-82Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease, diphtheria, Tetanus and 3 more, sponsored by GSK. Primary endpoint: Immune response to components of the investigational vaccine.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal diseasediphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on 2012-000819-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000819-82.